Please ensure Javascript is enabled for purposes of website accessibility

Did You Miss Out on the 4900% Gain With Vaxart Stock?

By Jim Crumly – Aug 19, 2020 at 6:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A potential COVID-19 vaccine in pill form elevated this former penny stock.

Come up with a pill that could end the worst health crisis in over a century, and you might find investors scrambling to buy your company's stock. That's exactly what's been going on with small-cap biotech stock Vaxart (VXRT -3.91%), and investors who owned the stock at the beginning of the year have seen their investment explode by a factor of 50.

Vaxart announced on Jan. 31 that it was working on a vaccine pill for the novel coronavirus that had recently been reported in Wuhan, China. That was good for a 71% pop in the stock price to $1.25, but the big gains came starting June 25, when the company announced it had signed a manufacturing deal with Attwill Medical Solutions Sterilflow, LP to crank out a billion doses of its COVID-19 vaccine pill. The next day, the company said its vaccine candidate had been selected for a non-human primate challenge study by Operation Warp Speed, and all of a sudden the market saw it as a serious contender in the COVID-19 vaccine race, with shares peaking at $17.49 on July 14.

Hand positioning blocks with percent signs of rising graph.

Image source: Getty Images.

Beside the advantages of the pill form, the clinical-stage biotech says its vaccine produces a type of antibody (IgA) that's secreted in mucosal cells, potentially providing extra protection against airborne transmission and differentiating it further from the competition.

Vaxart just took the first step toward human clinical trials on Aug. 10. The company has a long way to go to prove the vaccine actually works, and there's evidence that the IgA antibody to SARS-CoV-2 is short-lived, but investors willing to take a chance on the stock and who missed the big run can buy the shares for 47% less than July's peak.

Jim Crumly has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vaxart, Inc Stock Quote
Vaxart, Inc
$1.23 (-3.91%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.